The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jokiranta, T. S.
Right arrow Articles by Meri, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jokiranta, T. S.
Right arrow Articles by Meri, S.

The Journal of Immunology, Vol 151, Issue 4 2124-2131, Copyright © 1993 by American Association of Immunologists

ARTICLES

Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement

TS Jokiranta and S Meri
Department of Bacteriology and Immunology, University of Helsinki, Finland.

Biotinylation of mAb has become a standard procedure for a variety of applications that exploit the specific high affinity interaction between biotin and avidin. In the present study, we investigated how biotinylation of mAb affects their ability to sensitize target cells to C-dependent lysis in vitro. mAb were biotinylated by cross-linking biotin covalently with an N-succinimidyl ester to the epsilon-amino groups of lysine residues. Human RBC were treated with two rat mAb, either alone or together: one against glycophorin A (YTH89.1), another against CD59 (protectin; YTH53.1), an inhibitor of the membrane attack complex of C. Melanoma cells (G361) were attacked by a mouse mAb (27A) against an O-acetylated GD3 ganglioside. As compared with the nonbiotinylated mAb, the biotinylated forms of all the investigated mAb were much weaker in causing classical C pathway-mediated lysis of the target cells. Biotinylation did not reduce the ability of the mAb to bind to their Ag, nor of the anti-CD59 mAb to neutralize the C lysis- restrictive effect of CD59. In binding assays using 125I-labeled C1q, significantly less C1q bound to the biotinylated anti-glycophorin-A and anti-CD59 mAb than to the nonbiotinylated mAb. These data show that biotinylated antibodies do not activate the classical C pathway because binding of C1q to the antibody Fc-regions is blocked.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco
In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab
Cancer Res., November 1, 2007; 67(21): 10556 - 10563.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Lindorfer, A. Nardin, P. L. Foley, M. D. Solga, A. J. Bankovich, E. N. Martin, A. L. Henderson, C. W. Price, E. Gyimesi, C. P. Wozencraft, et al.
Targeting of Pseudomonas aeruginosa in the Bloodstream with Bispecific Monoclonal Antibodies
J. Immunol., August 15, 2001; 167(4): 2240 - 2249.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Hakulinen and S. Meri
Complement-Mediated Killing of Microtumors in Vitro
Am. J. Pathol., September 1, 1998; 153(3): 845 - 855.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Kaul and M. Loos
Dissection of C1q Capability of Interacting with IgG. TIME-DEPENDENT FORMATION OF A TIGHT AND ONLY PARTLY REVERSIBLE ASSOCIATION
J. Biol. Chem., December 26, 1997; 272(52): 33234 - 33244.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.